5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial.
One hundred and twenty-four migraineurs were treated randomly with 5-hydroxytryptophan (5-HTP) or with methysergide (M). The two groups were homogeneous without significant statistical differences with respect to age, sex, pill use, type of migraine and frequency of attacks before entry. A significant improvement was observed in 75% of the patients treated with M and in 71% of the cases treated with 5-HTP. The most beneficial effect of 5-HTP appears to be felt with regard to the intensity and duration rather than the frequency of the attacks. Side effects were more frequent in the M group than in the 5-HTP group. These results suggest that 5-HTP could be a treatment of choice in the prophylaxis of migraine.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008784:Methysergide / Q000627:therapeutic use*; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D011897:Random Allocation
D006916:5-Hydroxytryptophan; D008784:Methysergide